Testosterone for Women: The FDA Is Finally Listening
Here’s a fun fact that isn’t fun at all: men in the US have plenty of FDA-approved testosterone options. Women have zero. Not one testosterone product is FDA-approved for women, even though women make testosterone their whole lives and it plays a real role in desire.
That may finally be changing. Here’s what happened this fall, what the research actually supports, and what to watch for.
Why Everyone’s Talking About It Now
On September 17, 2026, the FDA held a public workshop on testosterone for menopausal women, hosted by its Office of Women’s Health. The agency said it “stands ready to have discussions with drug sponsors” and closed with a line we’d frame: “Menopause is inevitable, but women should not have to suffer” (Holland & Knight). The public comment period closed October 19 (Federal Register), with more than 1,320 comments submitted by the time of that report.
Meanwhile, testosterone is already approved for low desire after menopause in Australia, New Zealand, the UK and South Africa (Holland & Knight). And American women aren’t waiting: the number of women getting a testosterone prescription rose 146% from January 2023 to July 2026, according to a Truveta analysis for Reuters, even as many hit pharmacy denials and delays (Reuters via The Star).
What the Research Shows
The strongest evidence is for one thing, and it’s a big one: desire.
A 2019 meta-analysis in The Lancet Diabetes & Endocrinology pooled 36 randomized trials with 8,480 participants. In postmenopausal women, testosterone improved the number of satisfying sexual events, plus desire, arousal, orgasm, pleasure and self-image, and reduced sexual distress. Patches and creams didn’t disturb cholesterol the way oral testosterone did (Monash University).
That lines up with the 2019 Global Consensus Position Statement, endorsed by major medical societies: the one evidence-based use is postmenopausal women with hypoactive sexual desire disorder (HSDD), meaning low desire that causes real distress, diagnosed after a full assessment (Journal of Clinical Endocrinology & Metabolism). A blood test alone can’t diagnose it.
What It Doesn’t Do (Yet)
Testosterone is often marketed online as an energy, mood, muscle and anti-aging fix. The consensus statement found the evidence doesn’t support it for mood, wellbeing, bone density, muscle strength, body composition or brain health (JCEM). As Dr. Stephanie Faubion of The Menopause Society told Reuters, “We do not have any evidence in women that it will improve muscle mass or bone density” (Reuters via The Star). Those are open questions researchers want answered, not closed doors.
Side Effects: What to Know
• Acne and extra body or facial hair were more common with testosterone in trials (Monash University)
• Weight gain was reported overall in the pooled trials
• Cholesterol changes with oral forms (higher LDL, lower HDL), which is why oral testosterone isn’t recommended
• Long-term safety beyond 24 months is unknown, including heart and breast cancer risk; caution is advised with hormone-sensitive breast cancer (JCEM)
• Pellets, injections and compounded products aren’t recommended by the consensus statement, because they can push levels above the normal female range
New this month: research presented at The Menopause Society’s annual meeting in San Diego looked at more than 6,300 menopausal women aged 45 and older. Nearly 4% of women prescribed off-label testosterone had heart problems such as heart attack, stroke or heart failure, compared with 0.5% of those not prescribed it. The lead researcher noted absolute event rates were low, and the findings are preliminary until peer-reviewed (HealthDay via MedicineNet). It’s one more reason the FDA wants proper long-term trials.
When Should You Be Concerned?
Call 911 for chest pain, sudden weakness or numbness on one side, trouble speaking, or sudden shortness of breath. Talk to your clinician if you notice:
• Acne or facial hair that’s new or getting worse
• A deepening voice or thinning hair on your scalp (possible signs your levels are too high)
• Swelling in your legs or rapid weight gain
• No improvement in desire after six months (the consensus says to stop if there’s no benefit by then)
• You’re pregnant, trying to conceive, or have a history of breast cancer
If you’re already using testosterone, ask for your level to be checked. The consensus recommends a baseline test, a recheck after starting, and regular monitoring to stay in the female range.
Where Peptides Come In
Here’s the exciting part for us: testosterone isn’t the only path researchers are taking toward women’s desire, and two of the most promising ones are peptides.
PT-141 (bremelanotide) is already FDA-approved. Sold as Vyleesi, it was approved on June 21, 2019, for premenopausal women with acquired, generalized HSDD. In two 24-week trials with 1,247 women, about 25% on bremelanotide saw a meaningful jump in desire scores, vs. 17% on placebo. Nausea, flushing, headache and a temporary rise in blood pressure were the most common side effects (Healio). We covered it in depth in our PT-141 story.
Kisspeptin is the one to watch. It’s a natural peptide that sits at the very top of the reproductive hormone chain. In a 2023 Imperial College London trial in JAMA Network Open, 32 premenopausal women with HSDD received kisspeptin or placebo. Brain scans showed boosted activity in sexual and attraction areas, and women reported feeling “more sexy” on kisspeptin. It was well tolerated, and researchers are planning larger studies (Imperial College London). Kisspeptin is coming soon to The Peptide Files.
The big picture: women’s desire is finally getting serious scientific attention, from hormones to peptides that work on the brain. That’s a frontier we’ll keep following.
What We Know and What’s Next
We know: testosterone at female-range levels improves desire and satisfaction for postmenopausal women with HSDD, and the FDA is now openly looking for a path to approval.
The frontier: long-term heart and breast safety, the right dose, whether it helps premenopausal women, and whether it does anything for bone, muscle, mood or the brain.
The Bottom Line
Testosterone for women isn’t a fad or a fountain of youth. It’s a real treatment for a real problem, with good evidence for desire and open questions about long-term safety. The FDA listening is a big deal. Until an approved product arrives, the smart move is a clinician who measures, monitors and keeps you in the female range.
Your turn: Should the FDA approve a testosterone product made for women? Tell us why or why not.
This post is for educational purposes only and is not medical advice.
Sources
Comments